A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- and Placebo-Controlled Polysomnography Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Subjects With Insomnia Disorder

Trial Profile

A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- and Placebo-Controlled Polysomnography Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Subjects With Insomnia Disorder

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2018

At a glance

  • Drugs Seltorexant (Primary) ; Zolpidem
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development; Minerva Neurosciences
  • Most Recent Events

    • 11 Dec 2017 Planned number of patients changed to 360.
    • 06 Dec 2017 According to a Minerva Neurosciences media release, first patient has been enrolled.
    • 06 Dec 2017 Status changed from planning to recruiting, according to a Minerva Neurosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top